| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $4.0M | +43.2% | -63.8% |
| SG&A Expense | $6.3M | -15.0% | -47.0% |
| Operating Income | -$10.3M | -1.0% | +55.1% |
| Net Income | -$10.1M | -2.3% | +53.6% |
| EPS (Basic) | -$0.30 | +0.0% | +58.3% |
| EPS (Diluted) | -$0.30 | +0.0% | +58.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.4M | +2.3% | -6.7% |
| Short-term Investments | $12.5M | -35.1% | -76.2% |
| Current Assets | $14.9M | -29.6% | -73.3% |
| Total Assets | $14.9M | -29.6% | -73.3% |
| Current Liabilities | $5.2M | +1.1% | -35.8% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$31.2M | — | — |
| Investing Cash Flow | $28.8M | — | — |
| Financing Cash Flow | -$73K | — | — |
| $5.4M |
| +4.7% |
| -33.2% |
| Stockholders' Equity | $9.5M | -40.7% | -80.1% |